Projet TOLLerant (Horizon 2020, appel à projets 2014)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : CLOSED

Based on an international team derived from the COST action BM1003 (www.cost-bm1003.info, 2011-2014) and thus relying on consolidated group interactions and synergies and on a unique combination of chemistry, biology, biophysics, biochemistry and pharmacology expertise, the TOLLerant project aims to gain information on molecular aspects of TLR4 activation and signaling by using synthetic and natural compounds and nanoparticles that interact selectively with some components (mainly MD-2 and CD14) of the TRL4 recognition system. TLR4 is an emerging molecular target related to an impressively broad spectrum of modern day disorders still lacking specific pharmacological treatment. These include autoimmune disorders, chronic inflammations, allergies, asthma, infectious and CNS diseases and cancer. The short-term scientific objective is to develop novel, non-toxic, synthetic and natural TLR4 modulators (agonists or antagonists) and to assess their therapeutic potential on animal models of TLR4-related acute and chronic pathologies that still lack efficient pharmacological treatment. The long-term scientific objective is to develop a new generation of innovative, TLR4-based therapeutics, to be used as vaccine adjuvants, anti-sepsis agents, and anti-inflammatory agents to treat chronic inflammations (allergy, asthma). The training programme will provide Early Stage Researchers (ESR) with broad competences, experience and skills in the cutting-edge, inter-disciplinary research in the field of chemical biology related to the molecular mechanisms of innate immunity and inflammation. During the training, the young researchers will be supported by senior scientists to cultivate their scientific, entrepreneurial and inter-cultural mindset. The non-academic sector will be committed to provide ESRs with entrepreneurship and company management skills, in order to enhance their employability by the private sector or even to motivate them to create own start-up companies.

Mots clés : medicinal chemistry, ligand receptor interactions, lipid a, fluorescence, tlr4 signaling, nanoparticles, sepsis, asthma, infectious diseases

Participants :
- Vlaams Instituut voor Biotechnologie (Belgique) — Partner, beneficiary, Recherche, subvention : 250560.0 €
- National Institute of Chemistry (Slovénie) — Partner, beneficiary, Recherche, subvention : 469995.12 €
- Lofarma (Italy) (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 129030.66 €
- Bielefeld University (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- University of Milano-Bicocca (Italie) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 516122.64 €
- CIC biomaGUNE (Espagne) — Partner, beneficiary, Recherche, subvention : 247872.96 €
- CIC bioGUNE (Espagne) — Partner, beneficiary, Recherche, subvention : 247872.96 €
- Spanish National Research Council (Espagne) — Partner, beneficiary, Recherche, subvention : 247872.96 €
- University of Naples Federico II (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 516122.64 €
- Diomune sl (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 247872.96 €